Alana L. Welm

Alana L. Welm, PhD

Languages spoken: English

Academic Information

Departments Primary - Oncological Sciences

Lab

Alana Welm, PhD, is Senior Director of Basic Science at the Huntsman Comprehensive Cancer Center, Chair and Professor in the Department of Oncological Sciences at the University of Utah, and an Investigator at the Huntsman Cancer Institute. Welm's laboratory studies breast cancer metastasis.

Dr. Welm completed her PhD in Cell and Molecular Biology at Baylor College of Medicine in Houston, TX under the supervision of Gretchen Darlington, PhD. She then went on to conduct postdoctoral training in Dr. J. Michael Bishop’s laboratory at the University of California, San Francisco where her work focused on developing new models of breast cancer metastasis. Dr. Welm started her laboratory at the University of Utah’s Huntsman Cancer Institute in 2007, was promoted to Associate Professor with tenure in 2013, and granted Full Professorship in 2019.

The research in Dr. Welm’s laboratory is focused on solving the problem of breast cancer metastasis using in vivo modeling of mouse and human breast cancers. Dr. Welm’s group discovered that the Ron kinase pathway is an important facilitator of breast cancer metastasis through its unique dual function in tumor cells and in resident macrophages. Current areas of research include (1) pre-clinical studies of various Ron inhibitors for treatment and prevention of metastatic breast cancer; (2) pre-clinical and early clinical studies of Ron/Met inhibitors in bone metastatic cancers; (3) discovering molecular mechanisms by which Ron kinases promote metastasis through cell-autonomous and non cell-autonomous pathways; and (4) refining “precision medicine” for metastatic breast cancer using functional assays in patient-derived breast tumor grafts.

Education History

Undergraduate University of Montana
 BS
Doctoral Training Baylor College of Medicine
 PhD
Postdoctoral Fellowship University of California, San Francisco
 Postdoctoral Fellow

Selected Publications

Journal Article

  1. Fornetti J, Welm AL, Stewart SA (2018). Understanding the Bone in Cancer Metastasis. J Bone Miner Res, 33(12), 2099-2113.
  2. Larrieu-Lahargue F, Welm AL, Thomas KR, Li D (2010). Netrin-4 induces lymphangiogenesis in vivo. Blood, 115(26), 5418-26.
  3. Dustin D, Gu G, Beyer AR, Herzog SK, Edwards D, Lin H, Gonzalez T, Grimm S, Coarfa C, Chan DW, Kim B-J, De La O J-P, Ellis M, Liu D, Li S, Welm AL, and Fuqua SA RON signaling promotes therapeutic resistance in ESR1 mutant breast cancer. British journal of cancer,
  4. Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SA (2021). RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British journal of cancer, 124(1), 191-206.
  5. Riggio AI, Varley KE, Welm A (2021). The lingering mysteries of metastatic recurrence in breast cancer. British journal of cancer, 124(1), 13-26.
  6. Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle M (2014). Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Molecular biology of the cell, 25(18), 2695-709.
  7. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium., EurOPDX Consortium (2021). Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature genetics, 53(1), 86-99.
  8. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman (2013). Survivin promotion of melanoma metastasis requires upregulation of ¿5 integrin. Carcinogenesis, 34(9), 2137-44.
  9. Kim S, Welm AL, Bishop J (2010). A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer research, 70(12), 5155-62.
  10. Powers MA, Fay MM, Factor RE, Welm AL, Ullman K (2011). Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer research, 71(16), 5579-87.
  11. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich (2014). Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer research, 74(5), 1463-74.
  12. Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult C (2017). PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer research, 77(21), e62-e66.
  13. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas (2016). A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 167(1), 260-274.e22.
  14. Larrieu-Lahargue F, Welm AL, Thomas KR, Li D (2011). Netrin-4 activates endothelial integrin {alpha}6{beta}1. Circulation research, 109(7), 770-4.
  15. Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA, Board Members of the Metastasis Research Society (2019). The importance of developing therapies targeting the biological spectrum of metastatic disease. Clinical & experimental metastasis, 36(4), 305-309.
  16. Faham N, Welm A (2016). RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harbor symposia on quantitative biology, 81, 177-188.
  17. Welm AL, Mackey SL, Timchenko LT, Darlington GJ, Timchenko N (2000). Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/enhancer binding protein alpha mRNA. The Journal of biological chemistry, 275(35), 27406-13.
  18. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko L (2001). RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. The Journal of biological chemistry, 276(11), 7820-6.
  19. Welm AL, Timchenko NA, Ono Y, Sorimachi H, Radomska HS, Tenen DG, Lekstrom-Himes J, Darlington G (2002). C/EBPalpha is required for proteolytic cleavage of cyclin A by calpain 3 in myeloid precursor cells. The Journal of biological chemistry, 277(37), 33848-56.
  20. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford H (2009). Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. The Journal of clinical investigation, 119(9), 2663-77.
  21. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford H (2009). The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of clinical investigation, 119(9), 2678-90.
  22. Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver V (2010). HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. The Journal of clinical investigation, 120(5), 1535-50.
  23. Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier J (2018). Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. The Journal of clinical investigation, 128(1), 531-544.
  24. Song K, Cai X, Dong Y, Wu H, Wei Y, Shankavaram U, Cui K, Lee Y, Zhu B, Bhattacharjee S, Wang B, Zhang K, Wen A, Wong S, Yu L, Xia L, Welm AL, Bielenberg DR, Camphausen K, Kang Y, Chen (2020). Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development. . The Journal of clinical investigation,
  25. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna K (2013). Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of nuclear medicine, 54(6), 913-21.
  26. Welm AL, Timchenko NA, Darlington G (1999). C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage. Molecular and cellular biology, 19(3), 1695-704.
  27. Timchenko LT, Iakova P, Welm AL, Cai ZJ, Timchenko N (2002). Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Molecular and cellular biology, 22(20), 7242-57.
  28. Tavora B, Mederer T, Wessel KJ, Ruffing S, Sadjadi M, Missmahl M, Ostendorf BN, Liu X, Kim JY, Olsen O, Welm AL, Goodarzi H, Tavazoie S (2020). Tumoural activation of TLR3-SLIT2 axis in endothelium drives metastasis. Nature, 586(7828), 299-304.
  29. Timchenko NA, Welm AL, Lu X, Timchenko L (1999). CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms. Nucleic acids research, 27(22), 4517-25.
  30. Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald (2018). EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene, 37(30), 4073-4093.
  31. Yang D, Welm A, Bishop J (2004). Cell division and cell survival in the absence of survivin. Proceedings of the National Academy of Sciences of the United States of America, 101(42), 15100-5.
  32. Welm AL, Kim S, Welm BE, Bishop J (2005). MET and MYC cooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 102(12), 4324-9.
  33. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik C (2007). Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 104(14), 5771-6.
  34. Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer D (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 112(17), 5425-30.
  35. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, Van de Vijer MJ, Hasegawa BH, Bishop J (2007). The macrophage stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America, 104(18), 7570-7575.
  36. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop J (2007). The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America, 104(18), 7570-5.
  37. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm A (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature medicine, 17(11), 1514-20.
  38. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2019). Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(4), 620-627.
  39. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser M (2009). Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clinical cancer research, 15(7), 2311-22.
  40. Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm A (2015). Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clinical cancer research, 21(24), 5588-600.
  41. Giró-Perafita A, Palomeras S, Lum DH, Blancafort A, Viñas G, Oliveras G, Pérez-Bueno F, Sarrats A, Welm AL, Puig (2016). Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer. Clinical cancer research, 22(18), 4687-97.
  42. Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin A, Welm AL, Oesterreich S, Sikora MJ, Brown RE, Mills G (2016). High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype.LID - clincanres.0171.2016 [pii]. Clinical cancer research,
  43. Palomeras S, Diaz-Lagares A, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum D, Welm AL, Esteller N, and Puig Epigenetic Silencing of TGFBI Confers Resistance to Trastuzumab in Human Breast Cancer. Clinical cancer research,
  44. Smith BA, Welm AL, Welm B (2012). On the shoulders of giants: a historical perspective of unique experimental methods in mammary gland research. Seminars in cell & developmental biology, 23(5), 583-90.
  45. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, Timchenko N (2001). C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Molecular cell, 8(4), 817-28.
  46. Lloyd IE, Welm AL, DeRose Y, Neumayer LA, Kohan JL, Malmberg EM, Salama ME, Factor R (2018). X-Ray of Excised Cancerous Breast Tissue Does Not Affect Clinical Biomarker Expression. Applied immunohistochemistry & molecular morphology, 26(7), 501-508.
  47. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding W (2016). Plasma exosome microRNAs are indicative of breast cancer. Breast cancer research, 18(1), 90.
  48. Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, Esteller M, Puig (2019). Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast cancer research, 21(1), 79.
  49. Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge J (2020). Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast cancer research, 22(1), 132.
  50. Kretschmann KL, Eyob H, Buys SS, Welm A (2010). The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Current drug targets, 11(9), 1157-68.
  51. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow C (2012). Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer cell, 21(3), 430-46.
  52. Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, Mills GB, Brugge J (2018). Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer cell, 33(6), 985-1003.e7.
  53. Viswanath P, Welm A (2021). Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse. Cancer cell, 39(2), 148-150.
  54. Kessler JL, Li Y, Fornetti J, Welm AL, Yu S (2020). Enrichment of Collagen Fragments Using Dimeric Collagen Hybridizing Peptide for Urinary Collagenomics. Journal of proteome research, 19(8), 2926-2932.
  55. Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo K, Li DY, Bikfalvi A, Auguste (2012). Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PloS one, 7(6), e39540.
  56. Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb (2008). Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell stem cell, 2(1), 90-102.
  57. Lum DH, Matsen C, Welm AL, Welm B (2012). Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Current protocols in pharmacology, Chapter 14, Unit 14.22.
  58. DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm B (2013). Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Current protocols in pharmacology, Chapter 14, Unit14.23.
  59. Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm A (2017). RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Science translational medicine, 9(374),
  60. Feng Q, Zhang C, Lum D, Druso JE, Blank B, Wilson KF, Welm A, Antonyak MA, Cerione R (2017). A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nature communications, 8, 14450.
  61. Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic (2020). CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nature communications, 11(1), 798.
  62. Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C, Welm AL, Kang Y, Chakrabarti (2021). Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-¿B survival pathway. Nature communications, 12(1), 432.
  63. Sun H, Cao S, Mashl RJ, Mo C-K, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean II DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim K-H, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Dipersio JF, The NCI PDXNet Consortium, Davis-Dusenbery B, Lewis MT, Davies M, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature communications,
  64. Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm A (2011). Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes & cancer, 2(7), 753-62.
  65. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle M (2012). The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes & cancer, 3(2), 102-16.
  66. Moxley KM, Wang L, Welm AL, Bieniasz (2016). Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes & cancer, 7(5-6), 169-81.
  67. Zarei O, Faham N, Vankayalapati H, Raeppel SL, Welm AL, Hamzeh-Mivehroud (2020). Ligand-based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase. Molecular informatics, 41, e2000181.
  68. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm A (2013). Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer discovery, 3(7), 751-60.
  69. Olsen SN, Wronski A, Castano Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, Cichowski (2017). Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer discovery, 7(2), 202-217.
  70. Eyob H, Ekiz HA, Welm A (2013). RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. Oncoimmunology, 2(9), e25670.
  71. Ekiz HA, Lai SA, Gundlapalli H, Haroun F, Williams MA, Welm A (2018). Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. Oncoimmunology, 7(9), e1480286.
  72. DeVette CI, Gundlapalli H, Lai SA, McMurtrey CP, Hoover AR, Gurung HR, Chen WR, Welm AL, Hildebrand W (2019). A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer. Oncoimmunology, 9(1),
  73. Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm A (2014). The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell reports, 6(1), 141-54.
  74. DeVette CI, Andreatta M, Bardet W, Cate SJ, Jurtz VI, Jackson KW, Welm AL, Nielsen M, Hildebrand W (2018). NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer immunology research, 6(6), 636-644.
  75. Faham N, Zhao L, Welm A (2018). mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. NPJ breast cancer, 4, 36.
  76. Welm BE, Vaklavas C, Welm A (2021). Toward improved models of human cancer. APL bioengineering, 5(1), 010901.
  77. Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz A (2022). CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell reports, 38(9), 110448.
  78. Lai SA, Gundlapalli H, Ekiz HA, Jiang A, Fernandez E, Welm A (2021). Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression. Cancer discovery, 11(12), 3178-3197.
  79. Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens (2022). Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia,
  80. Arnesen S, Polaski JT, Blanchard Z, Osborne KS, Welm AL, O'Connell RM, Gertz (2023). Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs. NAR cancer, 5(2), zcad027.
  81. Quail DF, Park M, Welm AL, Ekiz H (2023). Breast Cancer Immunity: It is TIME for the Next Chapter. Cold Spring Harbor perspectives in medicine,
  82. Kidwell CU, Casalini JR, Pradeep S, Scherer SD, Greiner D, Bayik D, Watson DC, Olson GS, Lathia JD, Johnson JS, Rutter J, Welm AL, Zangle TA, Roh-Johnson (2023). Transferred mitochondria accumulate reactive oxygen species, promoting proliferation. eLife, 12,
  83. Petrosyan V, Dobrolecki LE, Thistlethwaite L, Lewis AN, Sallas C, Srinivasan RR, Lei JT, Kovacevic V, Obradovic P, Ellis MJ, Osborne CK, Rimawi MF, Pavlick A, Shafaee MN, Dowst H, Jain A, Saltzman AB, Malovannaya A, Marangoni E, Welm AL, Welm BE, Li S, Wulf GM, Sonzogni O, Huang C, Vasaikar S, Hilsenbeck SG, Zhang B, Milosavljevic A, Lewis M (2022). Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience, 26(1), 105799.
  84. Shree Bose, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen (2022). A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer cell, 40(12), 1448-1453.
  85. Nandi A, Debnath R, Nayak A, To TKJ, Thacker G, Reilly M, Gumber S, Karagounis I, Li N, Lengner CJ, Haldar M, Welm AL, Blanco AM, Thomas C, Chakrabarti (2022). Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer. Cancer research, 82(20), 3718-3733.
  86. Petrosyan V, Dobrolecki LE, LaPlante EL, Srinivasan RR, Bailey MH, Welm AL, Welm BE, Lewis MT, Milosavljevic (2022). Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts. NPJ breast cancer, 8(1), 104.
  87. Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H, PDXNet Consortium, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA 2nd, Chuang J (2022). PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR cancer, 4(2), zcac014.
  88. Hoover AR, Liu K, DeVette CI, Krawic JR, Medcalf AD, West CL, Hode T, Lam SSK, Welm AL, Sun XH, Hildebrand WH, Chen W (2022). Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clinical and translational medicine, 12(7), e937.
  89. Chew NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, Yang J, Hui MN, Deng N, McLean CA, Welm AL, Lim E, Gregory P, Nottle T, Lang T, Vereker M, Richardson G, Kerr G, Micati D, Jardé T, Abud HE, Lee RS, Swarbrick A, Daly R (2021). Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast cancer research, 23(1), 82.
  90. Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE, Linde IL, Guerrero M, Veatch JR, Snyder AG, Welm AL, Riddell SR, Ghajar C (2024). Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer cell, 42(1), 119-134.e12.
  91. Cannon-Albright LA, Stevens J, Teerlink CC, Facelli JC, Allen-Brady K, Welm A (2023). A Rare Variant in MDH2 (rs111879470) Is Associated with Predisposition to Recurrent Breast Cancer in an Extended High-Risk Pedigree. Cancers, 15(24),
  92. Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, Wyczalkowski MA, Mo CK, Liu R, Herndon JM, Davies SR, Liu D, Ding X, Evrard YA, Welm BE, Lum D, Koh MY, Welm AL, Chuang JH, Moscow JA, Meric-Bernstam F, Govindan R, Li S, Hsieh J, Fields RC, Lim KH, Ma CX, Zhang H, Ding L, Chen (2023). Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer research, 83(24), 4161-4178.
  93. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn (2023). Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer research, 83(19), 3284-3304.
  94. Scherer SD, Zhao L, Butterfield AJ, Yang CH, Cortes-Sanchez E, Guillen KP, Welm BE, Welm A (2023). Breast cancer PDxO cultures for drug discovery and functional precision oncology. STAR protocols, 4(3), 102402.
  95. Geukens T, Maetens M, Hooper JE, Oesterreich S, Lee AV, Miller L, Atkinson JM, Rosenzweig M, Puhalla S, Thorne H, Devereux L, Bowtell D, Loi S, Bacon ER, Ihle K, Song M, Rodriguez-Rodriguez L, Welm AL, Gauchay L, Murali R, Chanda P, Karacay A, Naceur-Lombardelli C, Bridger H, Swanton C, Jamal-Hanjani M, Kollath L, True L, Morrissey C, Chambers M, Chinnaiyan AM, Wilson A, Mehra R, Reichert Z, Carey LA, Perou CM, Kelly E, Maeda D, Goto A, Kulka J, Székely B, Szasz AM, T'kés AM, Van Den Bogaert W, Floris G, Desmedt (2024). Research autopsy programmes in oncology: shared experience from 14 centres across the world. The Journal of pathology,
  96. Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow J (2024). Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Molecular cancer therapeutics,
  97. Besse A, Sedlarikova L, Buechler L, Kraus M, Yang CH, Strakova N, Soucek K, Navratil J, Svoboda M, Welm AL, Joerger M, Driessen C, Besse (2024). HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. British journal of cancer,
  98. Lei JT, Dobrolecki LE, Huang C, Srinivasan RR, Vasaikar SV, Lewis AN, Sallas C, Zhao N, Cao J, Landua JD, Moon CI, Liao Y, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan V, Wen B, Li K, Saltzman AB, Jain A, Malovannaya A, Wulf GM, Marangoni E, Li S, Kraushaar DC, Wang T, Damodaran S, Zheng X, Meric-Bernstam F, Echeverria GV, Anurag M, Chen X, Welm BE, Welm AL, Zhang B, Lewis M (2024). Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses. bioRxiv,
  99. White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi Pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, PDXNet Consortium, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean DA 2nd, Chuang J (2024). A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer research, 84(13), 2060-2072.
  100. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, D'Astous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm A (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO precision oncology, 8, e2300724.
  101. Sederman C, Yang CH, Cortes-Sanchez E, Di Sera T, Huang X, Scherer SD, Zhao L, Chu Z, White ER, Atkinson A, Wagstaff J, Varley KE, Lewis MT, Qiao Y, Welm BE, Welm AL, Marth G (2024). A precision oncology-focused deep learning framework for personalized selection of cancer therapy. bioRxiv,
  102. Safe S, Oany AR, Upadhyay S, Tsui WN, Hailemariam A, Latka S, Landua J, Scherer S, Welm AL, Villanueva H, Lewis (2025). Orphan Nuclear Receptor 4A1 (NR4A1) and NR4A2are Endogenous Regulators of CD71 and TheirLigands Induce Ferroptosis in Breast Cancer. Research square,
  103. Andrews HS, Bado IL, Beumer A, Chan IS, Cowden J, Denardi D, Echeverria GV, Gates BL, Gilliam M, Hodgdon C, Lee AV, Mancuso J, Maues J, Oesterreich S, Papanicolaou M, Pendleton KE, Riter B, Shanahan K, Tran-Huynh AM, Viswanath P, Walker S, Welm AL, Williams MM, Wyatt GL, Newby (2025). The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research. NPJ breast cancer, 11(1), 60.
  104. Olsen SN, Anderson B, Hatton C, Chu Z, Simpkins C, Wen Y, Bourgeois W, Haarer EL, Brown M, Jeselsohn R, Welm AL, Toska E, Armstrong S (2025). Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. Cell reports. Medicine, 102192.
  105. Curtin MC, Jackson AE, Brown EA, Maschek JA, Lum D, Cox JE, Welm AL, Hilgendorf K (2025). Lean breast adipocytes secrete an oxylipin that suppresses breast cancer via ferroptosis. bioRxiv,
  106. De Martino D, Zapatería B, Dunne JB, Drapela S, Matteson K, Oruko D, Humphrey T, Jonhston T, Varghese BA, Riggio AI, Tiwary K, Bresnahan E, Barra J, Sowa A, Jenssen W, Sidoli S, Welm AL, Barroso M, Stallaert W, Gomes AP, Angel PM, Arias E, Bravo-Cordero J (2025). Collagen hydroxylation couples NAD+/NADH dynamics to tumor dormancy and reactivation. Research square,
  107. Oany AR, Upadhyay S, Tsui WNT, Hailemariam A, Latka S, Landua JD, Scherer SD, Welm AL, Villanueva H, Lewis MT, Safe (2025). Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 are endogenous regulators of CD71 and their ligands induce ferroptosis in breast cancer. Cell death & disease, 16(1), 776.
  108. Polanco ER, Moustafa TE, Balcioglu O, Scherer SD, Cortes-Sanchez E, Remick S, Spike BT, Welm AL, Welm BE, Bernard PS, Zangle T (2025). Determination of Drug Sensitivity in Patient Derived Models of Breast Cancer by Multiparametric QPI. bioRxiv,
  109. Lee KJ, Kao YC, Jiang A, Prokofyeva A, Tom LN, Jagirdar K, Smit DJ, Oey HM, Tan JM, Ainger SA, Huang N, Tuong ZK, Andersen S, Senabouth A, Powell JE, Lambie D, Schaider H, Soyer HP, Sturm RA, Welm AL, Grossman D, Judson-Torres RL, Stark M (2025). Subclinical Fields of BRAF V600E-Mutant Melanocytes Populate Human Skin and Are Enriched Around Melanoma and Naevi. The British journal of dermatology,
  110. Nishida-Aoki N, Zhu S, Chan M, Kang Y, Fujita M, Jiang X, McCabe M, Vaz JM, Davidson NE, Ghajar CM, Hansen K, Welm AL, Pillarisetty VG, Gujral T (2025). Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell reports. Medicine, 6(10), 102357.
  111. Abba M, Behbod F, Ceppi P, Chammas R, Clarke R, Dalotto T, De Siervi A, Gómez Abuin G, Gottifredi V, Hoadley KA, Jerry J, Juric D, Kordon E, Lanari C, Lee A, Mahmoud YD, Mandó P, Maurer J, Mauro F, Miller T, Muller WJ, Novaro V, Oesterreich S, Park C, Pettit S, Razavi P, Richer J, Roqué M, Rossi M, Salaberry PJ, Salatino M, Sciacca M, Vallone SA, Vilarullo RN, Vivanco M, Waisberg F, Welm A, Wolos V (2025). Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer. Medicina, 85(3), 586-596.
  112. Puvvula PK, Yu Y, Sullivan KR, Eyob H, Rosenberg J, Welm A, Huff C, Moon A (2021). Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation. Cell reports, 35(9), 109156.
  113. Dhimolea E, de Matos Simoes R, Kansara D, Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, Tang H, Glassner BJ, Liu Z, Gao D, Bryan J, Bender S, Roth J, Scheffer M, Jeselsohn R, Gray NS, Georgakoudi I, Vazquez F, Tsherniak A, Chen Y, Welm A, Duy C, Melnick A, Bartholdy B, Brown M, Culhane AC, Mitsiades C (2021). An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer cell, 39(2), 240-256.e11.

Review

  1. Kretschmann KL, Welm A (2012). Mouse models of breast cancer metastasis to bone. Cancer metastasis reviews, 31(3-4), 579-83.
  2. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis M (2016). Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer metastasis reviews, 35(4), 547-573.
  3. Welm A (2008). TGFbeta primes breast tumor cells for metastasis. Cell, 133(1), 27-8.
  4. Faham N, Welm A (2017). RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harb Symp Quant Biol. 2016;81:177-188. doi: 10.1101/sqb.2016.81.031377. Epub 2017 Jan 5. PMID: 28057847. Cold Spring Harbor symposia on quantitative biology,
  5. Smith BA, Welm AL, Welm B (2012). On the shoulders of giants: a historical perspective of unique experimental methods in mammary gland research. Semin Cell Dev Biol. 2012 Jul;23(5):583-90. doi: 10.1016/j.semcdb.2012.03.005. Epub 2012 Mar 9. PMID: 22425744; PMCID: PMC3398198. Seminars in cell & developmental biology,
  6. Kretschmann KL, Eyob H, Buys SS, Welm A (2010). The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Current drug metabolism,
  7. Lum D, Matsen C, Welm AL, Welm BE (2012). Human primary tumor graft models: their clinical relevance and utility in basic and translational oncology research. Current protocols in pharmacology, Chapter 14(Unit 14), 22.
  8. Letai A, Bhola P, Welm A (2022). Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer cell, 40(1), 26-35.
  9. Stires H, Bado I, Brown T, Carlson M, Chan IS, Echeverria GV, Ewald AJ, Lim B, Lloyd C, Maues J, Oesterreich S, Riter RN, Shanahan K, Welm AL, Newby (2022). Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. NPJ breast cancer, 8(1), 75.
  10. Blanchard Z, Brown EA, Ghazaryan A, Welm A (2024). PDX models for functional precision oncology and discovery science. Nature reviews. Cancer, 25(3), 153-166.

Book Chapter

  1. Hill WE, Bucklin DJ, Bullard JM, Galbraith AL, Jammi NV, Rettburg CC, Sawyer BS, Van Waes M (1995). Identification of ribosome-ligand interactions using cleavage reagents. 73, 1033-1039.

Conference Proceedings

  1. Welm A (2004). AACR Special Conference: Advances in Breast Cancer Research- Genetics, Biology, and Clinical Implications. Breast cancer research, 6, E6.

Case Report

  1. Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm A (2022). A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature cancer, 3(2), 232-250.

Abstract

  1. Welm AL, Timchenko NA, Darlington G (1999). C/EBP¿ regulates proteolytic cleavage of C/EBPß. FASEB journal, 13, A1483.
  2. Heide L. Ford, Chu-An Wang, Kimberly Christensen, Douglas Micalizzi, J. Chuck Harrell, Kathryn Horwitz, Karen Heichman, Alana Welm, Paul Jedlick (2009). The six1 homeobox gene regulates lymphoangiogenesis and metastasis in a mouse model of breast cancer. 100th Annual American Association for Cancer Research Meeting, Denver, CO.
  3. Ching Hang Wong, Frederick L. Baehner, Danislav S. Spassov, Deepika Ahuja, Donghui Wang, Byron Hann, Jimmy Blair, Kevan Shokat, Alana L. Welm, Mark M. Moasse (2009). Trask, a new biomarker of epithelial tumors with increased src kinase activity. 100th Annual American Association for Cancer Research Meeting, Denver, CO.
  4. Cecinio Ronquillo Jr., Alana L. Wel (2009). Macrophage stimulating protein may transiently increase a population of ALDH1A1high cells which in turn may be correlated to breast cancer cell lines¿ tumorignicity and metastatic potential. 100th Annual American Association for Cancer Research Meeting, Denver, CO.
  5. Eyob, H, Waltz, S, and Welm, A (2009). Elucidating the mechanism of MSP-mediated breast cancer metastasis. American Association for Cancer Research Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Diego, CA.
  6. Maddox J, Chong CA, Bishop JM, Welm A (2008). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone.
  7. Eyob, H, Waltz, S, and Welm, AL (2010). Elucidating the mechanism of MSP-mediated breast cancer metastasis. Cold Spring Harbor conference on The Biology of Cancer: Microenvironment, Metastasis and Therapeutics, Cold Spring Harbor, NY.
  8. Chaturvedi AP, Welm AL, Lessnick SL, and Beckerle MC (2011). Impact of EWS-FLI induced changes in gene expression and cell behavior for metastatic potential. AACR Annual Meeting, Washington, D.C.
  9. Matthew J. Sikora, Uma R. Chandran, David J. Dabbs, Alana L. Welm, and Steffi Oesterreic (2012). Endocrine resistance in invasive lobular carcinoma cells parallels unique estrogen-mediated gene expression. San Antonio Breast Cancer Symposium, San Antonio, TX.
  10. Kretschmann, K, Waltz S, Welm AL (2009). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone. Cancer and Bone Society International Meeting, Sydney, Australia.
  11. Chong,C., Maddox,J., Welm A (2009). Macrophage-stimulating protein promotes cell invasion in vitro through an epithelial-mesenchymal transitionI. 100th Annual American Association for Cancer Research Meeting, Denver, CO.
  12. Douglas S. Micalizzi, Kimberly L. Christensen, Paul Jedlicka, Dean Billheimer, Alana L. Welm, William P. Schiemann, Heide L. For (2009). The six1 homeoprotein induces transforming growth factor-¿ signaling, epithelial to mesenchymal transition, and breast cancer metastasis. 100th Annual American Association for Cancer Research Meeting, Denver, CO.
  13. DeRose YS, Wang G, Lin Y-C, Bernard PS, Buys SS, Ebbert MTW, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, and Welm AL (2011). Patient-derived tumor grafts authentically reflect tumor pathology, growth, metastasis, and disease outcomes. American Association for Cancer Research Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Francisco, CA.
  14. Kretschmann, K, Waltz S, and Welm AL (2011). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone. DOD Era of Hope Breast Cancer Conference, Orlando, FL.
  15. Eyob H, Kretschmann K, Waltz S, and Welm AL (2010). Mechanisms of breast cancer metastasis that are extrinsic to tumor cells. Joint Metastasis Research Society-AACR Conference on Metastasis, Philadelphia, PA.
  16. Kretschmann, K, Waltz S, and Welm AL (2010). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone. Gordon Conference on Mammary Gland Biology, Barga, Italy.
  17. Farabaugh S, Micalizzi D, Welm AL, and Ford H (2010). The Six1 homeoprotein is dependent on Eya2 to mediate TGF¿ signaling, EMT properties, and stem cell characteristics in breast cancer. Joint Metastasis Research Society-AACR Conference on Metastasis, Philadelphia, PA.

Other

  1. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium., EurOPDX Consortium (2021). Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature genetics, 53(5), 761.
  2. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2019). Publisher Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(5), 861.
  3. Welm A (2004). AACR Special Conference: Advances in Breast Cancer Research--Genetics, Biology, and Clinical Implications, Huntington Beach, California, USA, 8-12 October 2003. Breast cancer research, 6(1), E6.
  4. Dell (2005). Highlight on: "MET and MYC cooperate in mammary tumorigenesis" by Welm AL; Kim S; Welm BE; Bishop JM. Nature reviews. Cancer, 102, 4324-4329.
  5. Welm BE, Vaklavas C, Welm A (2021). Erratum: "Toward improved models of human cancer" [APL Bioeng. 5, 010901 (2021)]. APL bioengineering, 5(2), 029901.
  6. Faculty of 1000 Biolog (2007). Highlight on: "The macrophage stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans" by Welm AL, Sneddon JB, Taylor C, Nuyten DSA, Van de Vijer MJ, Hasegawa BH, Bishop JM. 104, 7570-5.
  7. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium., Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding (2022). Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature communications, 13(1), 294.
  8. Dai J, Cimino PJ, Gouin KH 3rd, Grzelak CA, Barrett A, Lim AR, Long A, Weaver S, Saldin LT, Uzamere A, Schulte V, Clegg N, Pisarsky L, Lyden D, Bissell MJ, Knott S, Welm AL, Bielas JH, Hansen KC, Winkler F, Holland EC, Ghajar C (2022). Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nature cancer, 3(1), 25-42.
  9. Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis M (2021). Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer research, 81(24), 6259-6272.
  10. Scherer SD, Riggio AI, Haroun F, DeRose YS, Ekiz HA, Fujita M, Toner J, Zhao L, Li Z, Oesterreich S, Samatar AA, Welm A (2021). An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast cancer research, 23(1), 100.
  11. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium., Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding (2021). Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nature communications, 12(1), 5086.
  12. Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C, Welm AL, Kang Y, Chakrabarti (2022). Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-¿B survival pathway. Nature communications, 13(1), 3927.
  13. Scherer SD, Zhao L, Butterfield AJ, Yang CH, Cortes-Sanchez E, Guillen KP, Welm BE, Welm A (2025). Breast cancer PDxO cultures for drug discovery and functional precision oncology. STAR protocols, 6(1), 103676.
  14. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2025). Author Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 31(6), 2069.
  15. Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SA (2025). Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British journal of cancer,

News & Podcasts

Huntsman Cancer Institute News